• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Crinetics Pharmaceuticals Inc. (Amendment)

    2/14/24 6:36:08 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CRNX alert in real time by email
    SC 13G/A 1 ss3005719_sc13ga.htm AMENDMENT NO. 5
     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 5)*

     

     

    Crinetics Pharmaceuticals, Inc.
    (Name of Issuer)

     

     

    Common Stock, Par Value $0.001 Per Share
    (Title of Class of Securities)

     

     

    22663K107
    (CUSIP Number)

     

     

    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    o Rule 13d-1(b)

    x Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

      

       

     

     

    CUSIP No. 22663K107  SCHEDULE 13G Page 2 of 7 Pages

     

             
    1

    NAME OF REPORTING PERSONS

     OrbiMed Capital GP VI LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) o

    (b) o

     
    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    1,667,360

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    1,667,360

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,667,360

    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES o
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    2.5%

    12

    TYPE OF REPORTING PERSON

    OO

     

     

     

     

     

     

     

       

     

     

    CUSIP No. 22663K107  SCHEDULE 13G Page 3 of 7 Pages

     

             
    1

    NAME OF REPORTING PERSONS

     OrbiMed Advisors LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) o

    (b) o

     
    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    1,667,360

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    1,667,360

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,667,360

    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES o
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    2.5%

    12

    TYPE OF REPORTING PERSON

    IA

     

     

     

     

     

       

     

     

    CUSIP No.  22663K107  SCHEDULE 13G Page 4 of 7 Pages

     

    Item 1.   (a) Name of Issuer:

    Crinetics Pharmaceuticals, Inc.

        (b) Address of Issuer’s Principal Executive Offices:

    6055 Lusk Boulevard

    San Diego, California 92121

    Item 2.   (a) Name of Person Filing:

    OrbiMed Capital GP VI LLC

    OrbiMed Advisors LLC

        (b) Address of Principal Business Office:

    601 Lexington Avenue, 54th Floor

    New York, NY 10022

        (c) Citizenship:

    Please refer to Item 4 on each cover page for each Reporting Person.

        (d) Title of Class of Securities:

    Common Stock, Par Value $0.001 Per Share

        (e) CUSIP No.:

    22663K107

     

     

     

     

     

     

     

       

     

     

     

    CUSIP No. 22663K107  SCHEDULE 13G Page 5 of 7 Pages

     

     

    Item 3.      

    OrbiMed Capital GP VI LLC (“GP VI”) is the general partner of OrbiMed Private Investments VI, LP. OrbiMed Advisors LLC is an investment advisor in accordance with ss.240.13d-1(b)(1)(ii)(E) and is the managing member of GP VI.

     

      

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

       

     

     

    CUSIP No. 22663K107  SCHEDULE 13G Page 6 of 7 Pages

     

     

    Item 4. Ownership:

    Information with respect to the Reporting Person’s ownership as of December 31, 2023 is incorporated by reference to items (5) - (9) and (11) of the cover page for the Reporting Person.

    Item 5. Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the Reporting Person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

    Not Applicable.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group.

    Not Applicable.

    Item 9. Notice of Dissolution of Group.

    Not Applicable.

    Item 10. Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

     

     

     

     

       

     

     

     

    CUSIP No. 22663K107  SCHEDULE 13G Page 7 of 7 Pages

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2024

     

      OrbiMed Advisors LLC
           
      By: /s/ Carl L. Gordon
        Name:  Carl L. Gordon
        Title:  Member
           
      OrbiMed Capital GP VI LLC
      By: OrbiMed Advisors LLC, its Managing Member
           
      By: /s/ Carl L. Gordon
        Name:  Carl L. Gordon
        Title:  Member of OrbiMed Advisors LLC

     

     

     

     

     

     

     

     

     

     

     

     

     

    Get the next $CRNX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CRNX

    DatePrice TargetRatingAnalyst
    3/25/2025$60.00Buy
    Stifel
    2/11/2025Buy
    TD Cowen
    2/4/2025Peer Perform
    Wolfe Research
    1/22/2025$55.00Hold → Buy
    Jefferies
    3/6/2024$68.00Buy
    Citigroup
    1/16/2024$50.00Overweight
    Morgan Stanley
    12/21/2023$35.00Hold
    Jefferies
    11/20/2023$35.00Overweight
    JP Morgan
    More analyst ratings

    $CRNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Scientific Officer Betz Stephen F. exercised 88,170 shares at a strike of $3.30 and sold $3,141,877 worth of shares (97,483 units at $32.23), decreasing direct ownership by 9% to 99,713 units (SEC Form 4)

      4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)

      6/16/25 4:48:09 PM ET
      $CRNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Deardorf Caren was granted 6,900 shares, increasing direct ownership by 73% to 16,300 units (SEC Form 4)

      4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)

      6/13/25 4:30:20 PM ET
      $CRNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Okey Stephanie was granted 6,900 shares, increasing direct ownership by 73% to 16,300 units (SEC Form 4)

      4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)

      6/13/25 4:30:20 PM ET
      $CRNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRNX
    SEC Filings

    See more
    • Crinetics Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)

      6/12/25 4:27:42 PM ET
      $CRNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Crinetics Pharmaceuticals Inc.

      SCHEDULE 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)

      5/12/25 10:28:12 AM ET
      $CRNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Crinetics Pharmaceuticals Inc.

      10-Q - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)

      5/8/25 4:14:38 PM ET
      $CRNX
      Biotechnology: Pharmaceutical Preparations
      Health Care